Association of pretreatment serum carcinoembryonic antigen levels with chemoradiation-induced downstaging and downsizing of rectal cancer

Yeo,Seung‑Gu

doi:10.3892/mco.2016.740

Association of pretreatment serum carcinoembryonic antigen levels with chemoradiation-induced downstaging and downsizing of rectal cancer

Authors:
- Seung‑Gu Yeo
View Affiliations

Affiliations: Department of Radiation Oncology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Cheonan 31151, Republic of Korea
Published online on: January 25, 2016 https://doi.org/10.3892/mco.2016.740
Pages: 631-635

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to identify pretreatment clinical parameters associated with preoperative chemoradiotherapy (CRT)‑induced downstaging and downsizing of locally advanced rectal cancer (LARC T3‑4 or N+). Data from 51 LARC patients, who received preoperative CRT and radical surgery between 2010 and 2013, were retrospectively analyzed. Rectal adenocarcinoma was histologically confirmed in all patients, who ranged in age between 41 and 81 years (median, 64 years). CRT consisted of 50.4 Gy pelvic radiotherapy with concurrent chemotherapy using 5‑fluorouracil and leucovorin. After a median interval of 7 weeks post‑CRT, the patients underwent total mesorectal excision. Downstaging was defined as the transition from cStage II‑III to ypStage 0‑I. The longest tumor diameter was measured pre- and post‑CRT using computed tomography or magnetic resonance imaging, and based on the surgical specimen, respectively. Downstaging was observed in 16 (31.4%) patients, including 5 (9.8%) with a pathological complete response. The median downsizing rate was 60%. The serum carcinoembryonic antigen (CEA) levels were 0.8‑153.9 ng/ml (median, 4.4 ng/ml). The maximum standardized uptake value was 4.7‑33.9 (median, 10.8). On univariate analysis, cT stage, tumor size and CEA level were associated with downstaging. On multivariate analysis, only CEA level (≤5 ng/ml) was a significant predictor of downstaging (odds ratio = 16.0; 95% confidence interval: 1.8‑146.7; P=0.014). CEA level was the only factor significantly associated with downsizing (>60%) in the univariate analysis. These results demonstrated that pretreatment serum CEA levels are significantly associated with downstaging as well as downsizing of LARC following preoperative CRT. Therefore, this parameter may be useful in personalizing the management of LARC patients.

View Figures

View References

1	Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
2	Lee JW, Lee JH, Kim JG, Oh ST, Chung HJ, Lee MA, Chun HG, Jeong SM, Yoon SC and Jang HS: Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: An institutional analysis. Radiat Oncol J. 31:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
3	Habr-Gama A, Gama-Rodrigues J and Perez RO: Is tailoring treatment of rectal cancer the only true benefit of long-course neoadjuvant chemoradiation? Dis Colon Rectum. 56:264–266. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fleming FJ and Monson JR: The contemporary (over)treatment of rectal cancer: The goldilocks effect. Dis Colon Rectum. 57:403–406. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, Choi DH, Nam H, Kim JS, Cho MJ, et al: Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcomes and prognostic significance of pathologic nodal status (KROG 09–01). Ann Surg. 252:998–1004. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yeo SG, Kim DY and Oh JH: Long-term survival without surgery following a complete response to pre-operative chemoradiotherapy for rectal cancer: A case series. Oncol Lett. 6:1573–1576. 2013.PubMed/NCBI
7	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). New York: Springer. 2010.
8	Compton C, Fenoglio-Preiser CM, Pettigrew N and Fielding LP: American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer. 88:1739–1757. 2000. View Article : Google Scholar : PubMed/NCBI
9	Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK and Cho CW: Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 93:145–150. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wallin U, Rothenberger D, Lowry A, Luepker R and Mellgren A: CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 56:859–868. 2013. View Article : Google Scholar : PubMed/NCBI
11	Restivo A, Zorcolo L, Cocco IM, Manunza R, Margiani C, Marongiu L and Casula G: Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol. 20:864–871. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yoon SM, Kim DY, Kim TH, Jung KH, Chang HJ, Koom WS, Lim SB, Choi HS, Jeong SY and Park JG: Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 69:1167–1172. 2007. View Article : Google Scholar : PubMed/NCBI
13	Sautter-Bihl ML, Hohenberger W, Fietkau R, Rödel C, Schmidberger H and Sauer R: Rectal cancer: When is the local recurrence risk low enough to refrain from the aim to prevent it? Strahlenther Onkol. 189:105–110. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zoccali M and Fichera A: Role of radiation in intermediate-risk rectal cancer. Ann Surg Oncol. 19:126–130. 2012. View Article : Google Scholar : PubMed/NCBI
15	Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, Sebag-Montefiore DJ, Tekkis P and Brown G: MERCURY study group: Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. Ann Surg. 253:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
16	Frasson M, Garcia-Granero E, Roda D, Flor-Lorente B, Roselló S, Esclapez P, Faus C, Navarro S, Campos S and Cervantes A: Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer. 117:3118–3125. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hawkes EA, Cunningham D, Tait D, Brown G and Chau I: Neoadjuvant chemotherapy alone for early-stage rectal cancer: An evolving paradigm? Semin Radiat Oncol. 21:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
18	Yeo SG, Kim DY, Park JW, Choi HS, Oh JH, Kim SY, Chang HJ, Kim TH and Sohn DK: Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer. Int J Radiat Oncol Biol Phys. 82:856–862. 2012. View Article : Google Scholar : PubMed/NCBI
19	Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
20	Lee NK, Kim DY, Kim SY, Oh JH, Park W, Choi DH, Nam TK and Lee KJ: Clinical outcomes of local excision following preoperative chemoradiotherapy for locally advanced rectal cancer. Cancer Res Treat. 46:158–164. 2014. View Article : Google Scholar : PubMed/NCBI